TAXIS Pharmaceuticals Announces $2.67 Million NIH Grant to Advance Research and Development of Combination Therapy to Combat Antibiotic-Resistant Pneumonia

TAXIS Pharmaceuticals' investigational efflux pump inhibitors have been shown to restore potency of FDA-approved antibiotics in animal studies. NORTH BRUNSWICK, N.J., May 1, 2024 /PRNewswire-PRWeb/ -- TAXIS Pharmaceuticals, a clinical stage company developing new classes of...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news